Source comparison
Best IGF-1 LR3 Dosage for Hyperplasia: Protocol Comparison
Rodent systemic IGF-1 5–20 mg/day Intraperitoneal infusion 8–12 weeks continuous 15–30% increase in fiber number; myonuclear addition confirmed via histology Gold standard for hyperplasia research; not replicable with peptide protocols due to dose scaling Vete
This comparison does not assign a generated winner or score.
- Rodent systemic IGF-1
- 5–20 mg/day
- Intraperitoneal infusion
- 8–12 weeks continuous
- 15–30% increase in fiber number; myonuclear addition confirmed via histology
- Gold standard for hyperplasia research; not replicable with peptide protocols due to dose scaling
- Veterinary livestock
- 100–500 mcg/day
- Intramuscular
- 4–8 weeks
- Improved feed efficiency; lean mass gain; fiber counts rarely reported
- Practical validation of anabolic effects; endpoints focus on carcass metrics, not fiber proliferation
- Bodybuilding empirical (conservative)
- 40–80 mcg/day
- Bilateral IM post-workout
- 4–6 weeks on, 4–6 weeks off
- Subjective muscle fullness; improved recovery; no biopsy data
- Most common range in human use; cost-effective; aligns with receptor saturation timelines
- Bodybuilding empirical (aggressive)
- 100–150 mcg/day
- Bilateral IM
- 6 weeks on, 6 weeks off
- Enhanced muscle fullness; increased hypoglycemia risk; joint discomfort reports
- Higher risk of side effects; diminishing returns beyond 120 mcg/day; no evidence of superior hyperplasia
- Research peptide supplier recommendation
- 20–40 mcg/day
- Subcutaneous
- 4 weeks on, 4 weeks off
- Minimal anecdotal feedback; likely sub-threshold for measurable anabolic effects
- Dosage may be insufficient to saturate IGF-1R; below empirical effective range